KR20210055856A - Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof - Google Patents
Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof Download PDFInfo
- Publication number
- KR20210055856A KR20210055856A KR1020190141956A KR20190141956A KR20210055856A KR 20210055856 A KR20210055856 A KR 20210055856A KR 1020190141956 A KR1020190141956 A KR 1020190141956A KR 20190141956 A KR20190141956 A KR 20190141956A KR 20210055856 A KR20210055856 A KR 20210055856A
- Authority
- KR
- South Korea
- Prior art keywords
- vegf
- plgf
- pannus
- rheumatoid arthritis
- protein
- Prior art date
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 94
- 241001111421 Pannus Species 0.000 title claims abstract description 42
- 239000000090 biomarker Substances 0.000 title abstract description 19
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 95
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 95
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 95
- 108010082093 Placenta Growth Factor Proteins 0.000 claims abstract description 94
- 102000003666 Placenta Growth Factor Human genes 0.000 claims abstract description 94
- 210000002966 serum Anatomy 0.000 claims abstract description 46
- 210000001179 synovial fluid Anatomy 0.000 claims abstract description 46
- 238000002604 ultrasonography Methods 0.000 claims abstract description 27
- 230000009266 disease activity Effects 0.000 claims abstract description 18
- 230000035755 proliferation Effects 0.000 claims abstract description 13
- 238000009552 doppler ultrasonography Methods 0.000 claims abstract description 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 29
- 102100032752 C-reactive protein Human genes 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 108020004999 messenger RNA Proteins 0.000 claims description 15
- 210000000265 leukocyte Anatomy 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 210000000440 neutrophil Anatomy 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 8
- 206010023232 Joint swelling Diseases 0.000 claims description 7
- 108091023037 Aptamer Proteins 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 229930014626 natural product Natural products 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 39
- 108090001005 Interleukin-6 Proteins 0.000 description 32
- 201000004595 synovitis Diseases 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- -1 sFlt-1 Proteins 0.000 description 11
- 238000010586 diagram Methods 0.000 description 8
- 201000008482 osteoarthritis Diseases 0.000 description 8
- 210000001258 synovial membrane Anatomy 0.000 description 8
- 210000002437 synoviocyte Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000008718 systemic inflammatory response Effects 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 108010038633 aspartylglutamate Proteins 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- BECXEHHOZNFFFX-IHRRRGAJSA-N Arg-Ser-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BECXEHHOZNFFFX-IHRRRGAJSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- FLQAKQOBSPFGKG-CIUDSAMLSA-N Glu-Cys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FLQAKQOBSPFGKG-CIUDSAMLSA-N 0.000 description 2
- LZEUDRYSAZAJIO-AUTRQRHGSA-N Glu-Val-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LZEUDRYSAZAJIO-AUTRQRHGSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 206010023203 Joint destruction Diseases 0.000 description 2
- CGHXMODRYJISSK-NHCYSSNCSA-N Leu-Val-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O CGHXMODRYJISSK-NHCYSSNCSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- RSPUIENXSJYZQO-JYJNAYRXSA-N Phe-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RSPUIENXSJYZQO-JYJNAYRXSA-N 0.000 description 2
- PUEWAXRPXOEQOW-HJGDQZAQSA-N Thr-Met-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(O)=O PUEWAXRPXOEQOW-HJGDQZAQSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012362 drug development process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- ZIBWKCRKNFYTPT-ZKWXMUAHSA-N Ala-Asn-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O ZIBWKCRKNFYTPT-ZKWXMUAHSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 1
- ANNKVZSFQJGVDY-XUXIUFHCSA-N Ala-Val-Pro-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 ANNKVZSFQJGVDY-XUXIUFHCSA-N 0.000 description 1
- YUGFLWBWAJFGKY-BQBZGAKWSA-N Arg-Cys-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O YUGFLWBWAJFGKY-BQBZGAKWSA-N 0.000 description 1
- VDBKFYYIBLXEIF-GUBZILKMSA-N Arg-Gln-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VDBKFYYIBLXEIF-GUBZILKMSA-N 0.000 description 1
- PPMTUXJSQDNUDE-CIUDSAMLSA-N Asn-Glu-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PPMTUXJSQDNUDE-CIUDSAMLSA-N 0.000 description 1
- FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 1
- ZTRJUKDEALVRMW-SRVKXCTJSA-N Asn-His-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZTRJUKDEALVRMW-SRVKXCTJSA-N 0.000 description 1
- OSZBYGVKAFZWKC-FXQIFTODSA-N Asn-Pro-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O OSZBYGVKAFZWKC-FXQIFTODSA-N 0.000 description 1
- HPASIOLTWSNMFB-OLHMAJIHSA-N Asn-Thr-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O HPASIOLTWSNMFB-OLHMAJIHSA-N 0.000 description 1
- OERMIMJQPQUIPK-FXQIFTODSA-N Asp-Arg-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O OERMIMJQPQUIPK-FXQIFTODSA-N 0.000 description 1
- DBWYWXNMZZYIRY-LPEHRKFASA-N Asp-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O DBWYWXNMZZYIRY-LPEHRKFASA-N 0.000 description 1
- HJZLUGQGJWXJCJ-CIUDSAMLSA-N Asp-Pro-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJZLUGQGJWXJCJ-CIUDSAMLSA-N 0.000 description 1
- JGLWFWXGOINXEA-YDHLFZDLSA-N Asp-Val-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JGLWFWXGOINXEA-YDHLFZDLSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- DEVDFMRWZASYOF-ZLUOBGJFSA-N Cys-Asn-Asp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O DEVDFMRWZASYOF-ZLUOBGJFSA-N 0.000 description 1
- YMBAVNPKBWHDAW-CIUDSAMLSA-N Cys-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N YMBAVNPKBWHDAW-CIUDSAMLSA-N 0.000 description 1
- GUKYYUFHWYRMEU-WHFBIAKZSA-N Cys-Gly-Asp Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O GUKYYUFHWYRMEU-WHFBIAKZSA-N 0.000 description 1
- WTNLLMQAFPOCTJ-GARJFASQSA-N Cys-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CS)N)C(=O)O WTNLLMQAFPOCTJ-GARJFASQSA-N 0.000 description 1
- VDUPGIDTWNQAJD-CIUDSAMLSA-N Cys-Lys-Cys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CS)C(O)=O VDUPGIDTWNQAJD-CIUDSAMLSA-N 0.000 description 1
- QQAYIVHVRFJICE-AEJSXWLSSA-N Cys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N QQAYIVHVRFJICE-AEJSXWLSSA-N 0.000 description 1
- LPBUBIHAVKXUOT-FXQIFTODSA-N Cys-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N LPBUBIHAVKXUOT-FXQIFTODSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- QFJPFPCSXOXMKI-BPUTZDHNSA-N Gln-Gln-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N QFJPFPCSXOXMKI-BPUTZDHNSA-N 0.000 description 1
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 1
- WOMUDRVDJMHTCV-DCAQKATOSA-N Glu-Arg-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOMUDRVDJMHTCV-DCAQKATOSA-N 0.000 description 1
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 1
- FKGNJUCQKXQNRA-NRPADANISA-N Glu-Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O FKGNJUCQKXQNRA-NRPADANISA-N 0.000 description 1
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 1
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 description 1
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 1
- ZGEJRLJEAMPEDV-SRVKXCTJSA-N Glu-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)N ZGEJRLJEAMPEDV-SRVKXCTJSA-N 0.000 description 1
- HQOGXFLBAKJUMH-CIUDSAMLSA-N Glu-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N HQOGXFLBAKJUMH-CIUDSAMLSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 1
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- VCDNHBNNPCDBKV-DLOVCJGASA-N His-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VCDNHBNNPCDBKV-DLOVCJGASA-N 0.000 description 1
- LYSVCKOXIDKEEL-SRVKXCTJSA-N His-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CN=CN1 LYSVCKOXIDKEEL-SRVKXCTJSA-N 0.000 description 1
- MWXBCJKQRQFVOO-DCAQKATOSA-N His-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CN=CN1)N MWXBCJKQRQFVOO-DCAQKATOSA-N 0.000 description 1
- NDKSHNQINMRKHT-PEXQALLHSA-N His-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N NDKSHNQINMRKHT-PEXQALLHSA-N 0.000 description 1
- LQGCNWWLGGMTJO-ULQDDVLXSA-N His-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N LQGCNWWLGGMTJO-ULQDDVLXSA-N 0.000 description 1
- WYKXJGWSJUULSL-AVGNSLFASA-N His-Val-Arg Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O WYKXJGWSJUULSL-AVGNSLFASA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- NULSANWBUWLTKN-NAKRPEOUSA-N Ile-Arg-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N NULSANWBUWLTKN-NAKRPEOUSA-N 0.000 description 1
- PNDMHTTXXPUQJH-RWRJDSDZSA-N Ile-Glu-Thr Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@H](O)C)C(=O)O PNDMHTTXXPUQJH-RWRJDSDZSA-N 0.000 description 1
- GLYJPWIRLBAIJH-UHFFFAOYSA-N Ile-Lys-Pro Natural products CCC(C)C(N)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O GLYJPWIRLBAIJH-UHFFFAOYSA-N 0.000 description 1
- GLYJPWIRLBAIJH-FQUUOJAGSA-N Ile-Lys-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N GLYJPWIRLBAIJH-FQUUOJAGSA-N 0.000 description 1
- UFRXVQGGPNSJRY-CYDGBPFRSA-N Ile-Met-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N UFRXVQGGPNSJRY-CYDGBPFRSA-N 0.000 description 1
- VOCZPDONPURUHV-QEWYBTABSA-N Ile-Phe-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VOCZPDONPURUHV-QEWYBTABSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- CNNQBZRGQATKNY-DCAQKATOSA-N Leu-Arg-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N CNNQBZRGQATKNY-DCAQKATOSA-N 0.000 description 1
- RVVBWTWPNFDYBE-SRVKXCTJSA-N Leu-Glu-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVVBWTWPNFDYBE-SRVKXCTJSA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- RVOMPSJXSRPFJT-DCAQKATOSA-N Lys-Ala-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVOMPSJXSRPFJT-DCAQKATOSA-N 0.000 description 1
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 1
- CENKQZWVYMLRAX-ULQDDVLXSA-N Lys-Phe-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CENKQZWVYMLRAX-ULQDDVLXSA-N 0.000 description 1
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 1
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- ONGCSGVHCSAATF-CIUDSAMLSA-N Met-Ala-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O ONGCSGVHCSAATF-CIUDSAMLSA-N 0.000 description 1
- QDMUMFDBUVOZOY-GUBZILKMSA-N Met-Arg-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N QDMUMFDBUVOZOY-GUBZILKMSA-N 0.000 description 1
- WDTLNWHPIPCMMP-AVGNSLFASA-N Met-Arg-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O WDTLNWHPIPCMMP-AVGNSLFASA-N 0.000 description 1
- UAPZLLPGGOOCRO-IHRRRGAJSA-N Met-Asn-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N UAPZLLPGGOOCRO-IHRRRGAJSA-N 0.000 description 1
- BJPQKNHZHUCQNQ-SRVKXCTJSA-N Met-Pro-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCSC)N BJPQKNHZHUCQNQ-SRVKXCTJSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000595924 Mus musculus Placenta growth factor Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- UNLYPPYNDXHGDG-IHRRRGAJSA-N Phe-Gln-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 UNLYPPYNDXHGDG-IHRRRGAJSA-N 0.000 description 1
- YVXPUUOTMVBKDO-IHRRRGAJSA-N Phe-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CS)C(=O)O YVXPUUOTMVBKDO-IHRRRGAJSA-N 0.000 description 1
- HBXAOEBRGLCLIW-AVGNSLFASA-N Phe-Ser-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N HBXAOEBRGLCLIW-AVGNSLFASA-N 0.000 description 1
- KUSYCSMTTHSZOA-DZKIICNBSA-N Phe-Val-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N KUSYCSMTTHSZOA-DZKIICNBSA-N 0.000 description 1
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 1
- HQVPQXMCQKXARZ-FXQIFTODSA-N Pro-Cys-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O HQVPQXMCQKXARZ-FXQIFTODSA-N 0.000 description 1
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 1
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- JJKSSJVYOVRJMZ-FXQIFTODSA-N Ser-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)CN=C(N)N JJKSSJVYOVRJMZ-FXQIFTODSA-N 0.000 description 1
- YMEXHZTVKDAKIY-GHCJXIJMSA-N Ser-Asn-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)C(O)=O YMEXHZTVKDAKIY-GHCJXIJMSA-N 0.000 description 1
- KMWFXJCGRXBQAC-CIUDSAMLSA-N Ser-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N KMWFXJCGRXBQAC-CIUDSAMLSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 1
- UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 1
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 description 1
- KXFYAQUYJKOQMI-QEJZJMRPSA-N Trp-Ser-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 KXFYAQUYJKOQMI-QEJZJMRPSA-N 0.000 description 1
- BOBZBMOTRORUPT-XIRDDKMYSA-N Trp-Ser-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 BOBZBMOTRORUPT-XIRDDKMYSA-N 0.000 description 1
- VNRTXOUAOUZCFW-WDSOQIARSA-N Trp-Val-His Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O VNRTXOUAOUZCFW-WDSOQIARSA-N 0.000 description 1
- AZZLDIDWPZLCCW-ZEWNOJEFSA-N Tyr-Ile-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O AZZLDIDWPZLCCW-ZEWNOJEFSA-N 0.000 description 1
- YKCXQOBTISTQJD-BZSNNMDCSA-N Tyr-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YKCXQOBTISTQJD-BZSNNMDCSA-N 0.000 description 1
- XJPXTYLVMUZGNW-IHRRRGAJSA-N Tyr-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O XJPXTYLVMUZGNW-IHRRRGAJSA-N 0.000 description 1
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 1
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 1
- QHSSPPHOHJSTML-HOCLYGCPSA-N Val-Trp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N QHSSPPHOHJSTML-HOCLYGCPSA-N 0.000 description 1
- JSOXWWFKRJKTMT-WOPDTQHZSA-N Val-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N JSOXWWFKRJKTMT-WOPDTQHZSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 108010022588 methionyl-lysyl-proline Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000007488 musculoskeletal ultrasound Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
본 발명은 류마티스 관절염의 판누스 진단용 바이오마커 및 이의 이용에 관한 것이다.The present invention relates to a biomarker for diagnosing pannus of rheumatoid arthritis and its use.
류마티스 관절염(rheumatoid arthritis, 이하 RA)은 대표적인 자가면역질환으로, 관절 주위를 둘러싸고 있는 활막이라는 조직의 염증 때문에 일어나며, 전체 인구의 약 1~2% 가량이 발병하는 것으로 알려진 질환이다. 류마티스 관절염의 발병은 유전적-환경적 인자가 작용하며, 유전적인 요인이 대략 60% 정도 기여하는 것으로 알려져 있다. 대표적인 증상은 활막관절(synovial joint)에 나타나는 염증으로, 관절이 붓고 통증이 있으며, 질환이 발전하면 영구적으로 관절이 변형되고 관절의 기능에 심각한 손상을 주어 삶의 질이 크게 저하된다. 류마티스 관절염은 질병활성도가 조절되지 않으면 시간 경과에 따라 비가역적 관절변형과 장애가 발생하며 이를 조절하기 위한 면역억제제 및 생물학적 제제 등에 대한 약물반응 정도에 따라 관절파괴가 영향을 받는다.Rheumatoid arthritis (RA) is a representative autoimmune disease, which is caused by inflammation of a tissue called the synovial membrane surrounding the joint, and is known to affect about 1 to 2% of the total population. The onset of rheumatoid arthritis is caused by genetic-environmental factors, and genetic factors are known to contribute approximately 60%. A typical symptom is inflammation that appears in the synovial joint, and there is swelling and pain in the joint, and when the disease develops, the joint is permanently deformed and the function of the joint is severely damaged, which greatly reduces the quality of life. In rheumatoid arthritis, if the disease activity is not regulated, irreversible joint deformities and disorders occur over time, and joint destruction is affected by the degree of drug reaction to immunosuppressants and biological agents to control them.
초기 류마티스성 관절염은 처음에 더 작은 관절, 예컨대 손목, 손, 발목 및 발의 관절에 영향을 미치며 질환이 진행됨에 따라, 어깨, 팔꿈치, 무릎, 둔부, 턱 및 목의 관절들에도 영향을 나타낼 수 있다. 또한, 관절 내 부위 또는 관절 주변 부위에만 영향을 미치는 다른 관절염 상태들과는 달리, 류마티스성 관절염은 피부, 혈관, 심장, 폐 및 근육을 포함하는 신체에 걸쳐 관절외 조직에서 염증을 야기할 수 있는 전신성 질환이다. 한번 발병이 시작되면 꾸준히 악화되고 관절에 심각한 염증과 통증이 증가하는 질병인 류마티스성 관절염에 대한 적절한 치료방법이 없기 때문에 류마티스성 관절염의 초기 진단이 매우 중요하나 아직까지 류마티스성 관절염의 발병 및 진행 정도를 조기에 진단하는 기술 또한 미흡하여 이에 대한 연구 및 개발이 필요한 실정이다.Early rheumatoid arthritis initially affects smaller joints, such as the joints of the wrist, hand, ankle and foot, and as the disease progresses, it may also affect the joints of the shoulder, elbow, knee, hip, jaw and neck. . Also, unlike other arthritis conditions that affect only the intra-articular or peri-articular areas, rheumatoid arthritis is a systemic disease that can cause inflammation in extra-articular tissues throughout the body, including the skin, blood vessels, heart, lungs, and muscles. to be. The initial diagnosis of rheumatoid arthritis is very important because there is no adequate treatment method for rheumatoid arthritis, a disease that steadily worsens once the onset begins and increases severe inflammation and pain in the joints, but the onset and progression of rheumatoid arthritis is still very important. The technology for early diagnosis is also insufficient, so research and development on this is necessary.
류마티스 관절염의 진단에서는 누구나 인정할 수 있는 생화학적 지표나 병리소견, 영상소견 등의 소위 골드 스탠다드가 없기 때문에 여러 지표의 조합을 사용한 분류기준이라는 방법을 통하여 진단하게 된다. 류마티스 인자는 1987년 이후로 미국 류마티스학회 (American College of Rheumatology, ACR)에서 류마티스 진단에서 혈청학적 검사로 사용되고 있다. 류마티스 인자는 면역글로블린 IgG의 Fc 영역에 결합하는 자가항체이며, 류마티스 관절염 환자의 약 80%에서 증가되어 있지만, 관절염에 대한 특이도가 높지 않으며, 다른 자가 면역 질환이나 만성 염증, 악성종양, 건강한 노인에게서도 나타나는 단점이 있다.In the diagnosis of rheumatoid arthritis, there are no biochemical indicators, pathological findings, and so-called gold standards such as imaging findings that anyone can recognize, so the diagnosis is made through a method called classification criteria using a combination of several indicators. Rheumatoid factor has been used as a serological test in the diagnosis of rheumatism by the American College of Rheumatology (ACR) since 1987. Rheumatoid factor is an autoantibody that binds to the Fc region of immunoglobulin IgG, and is increased in about 80% of patients with rheumatoid arthritis, but has not high specificity for arthritis, and other autoimmune diseases, chronic inflammation, malignancies, and healthy elderly There is also a drawback that appears in
한편, 류마티스 관절염 발병 후 질환이 발전하면서 관절의 염증을 증가시키고, 나아가 관절의 파괴를 진행시키는 가장 큰 직접적인 요인은 판누스(pannus)의 증식이라고 할 수 있는데, 정상 관절의 경우 1~2겹 정도의 세포층으로 이루어져 있는 활막(synovial membrane)은 점성을 띄는 세포외 기질(extracellular matrix) 등을 만들어 내면서 관절의 윤활에 필수적인 활액(synovial fluid)을 유지시키는 중요한 역할을 하는 반면, 류마티스 관절염을 통해서 지속적인 염증성 환경에 노출된 활막세포들은 과다하게 증식하여 여러겹의 세포층을 형성하게 되고, 염증성 사이토카인을 생산하며 침윤성을 획득하여 연골을 파괴하고 관절의 파괴에 주요하게 기여하게 된다. 이와 같이 류마티스 관절염 활막관절에서 과다하게 증식된 활막의 덩어리를 일컬어 판누스 (pannus)라고 하며, 판누스의 증식 및 활성 정도는 관절염의 진행 정도를 나타내는 지표라고 할 수 있다. 그러므로, 판누스 관련 인자들은 신뢰성 있는 류마티스 관절염 바이오마커로 충분히 제시될 수 있다.Meanwhile, as the disease develops after the onset of rheumatoid arthritis, the most direct factor that increases joint inflammation and further promotes joint destruction is the proliferation of pannus. The synovial membrane, which is made up of the cell layer, plays an important role in maintaining the synovial fluid essential for joint lubrication while creating a viscous extracellular matrix. The synovial cells exposed to the environment proliferate excessively to form multiple cell layers, produce inflammatory cytokines, acquire invasiveness, destroy cartilage, and contribute to the destruction of joints. As such, a mass of the synovial membrane that is excessively proliferated in the synovial joint of rheumatoid arthritis is referred to as pannus, and the degree of proliferation and activity of pannus can be said to be an index indicating the progression of arthritis. Therefore, pannus-related factors can be sufficiently suggested as reliable rheumatoid arthritis biomarkers.
이에, 본 발명자들은 판누스의 병적 상태를 신속 간편하면서도 즉각적으로 진단할 수 있는 바이오마커를 개발함으로써 류마티스 관절염의 진단 등에 활용하고자 하였다.Accordingly, the present inventors have developed a biomarker that can quickly and conveniently diagnose pannus' pathological condition immediately, thereby utilizing it for diagnosing rheumatoid arthritis.
본 발명자들은 판누스의 병적 상태를 가장 잘 표현해 낼 수 있는 바이오마커를 발굴해내기 위해 연구를 진행한 결과, 활막세포에서 생산되는 주요 신생혈관형성(angiogenesis)과 관련된 인자 중 활액 PlGF 검출량이 임상적 염증수치, 판누스의 증식 정도를 나타내는 GSUS, 및 혈관형성 정도를 나타내는 PDUS 수준과 유의한 상관관계를 가지는 것을 확인하였으며, 혈청 VEGF 검출량은 질병활성도, GSUS, 및 PDUS 수준과 유의한 상관관계를 가지는 것을 확인하였다.The present inventors conducted research to discover a biomarker that can best express the pathological state of pannus. As a result, the amount of synovial PlGF detected among the major angiogenesis-related factors produced by synovial cells was clinically determined. It was confirmed that there was a significant correlation with the level of inflammation, GSUS indicating the degree of pannus proliferation, and the level of PDUS indicating the degree of angiogenesis, and the amount of serum VEGF detected was significantly correlated with the level of disease activity, GSUS, and PDUS. Confirmed.
이에, 본 발명의 목적은 PlGF(placenta growth factor) 및 VEGF(vascular endothelial growth factor)로 이루어진 군으로부터 선택되는 하나 이상을 포함하는, 류마티스 관절염의 판누스(pannus) 진단용 바이오마커 조성물 및 이의 이용을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a biomarker composition for diagnosing pannus of rheumatoid arthritis, including at least one selected from the group consisting of a placenta growth factor (PlGF) and a vascular endothelial growth factor (VEGF), and a use thereof. It is to do.
그러나, 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 본 발명이 속하는 기술 분야의 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.However, the technical task to be achieved by the present invention is not limited to the above-mentioned tasks, and other tasks that are not mentioned can be clearly understood by those of ordinary skill in the technical field to which the present invention belongs from the following description. There will be.
상기와 같은 목적을 달성하기 위해 본 발명은 PlGF(placenta growth factor) 및 VEGF(vascular endothelial growth factor)로 이루어진 군으로부터 선택되는 하나 이상을 포함하는, 류마티스 관절염의 판누스(pannus) 진단용 바이오마커 조성물을 제공한다.In order to achieve the above object, the present invention provides a biomarker composition for diagnosing pannus of rheumatoid arthritis, comprising at least one selected from the group consisting of placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF). to provide.
또한, 본 발명은 상기 PlGF 또는 VEGF의 발현 또는 활성 수준을 측정하는 제제를 포함하는, 류마티스 관절염의 판누스(pannus) 진단용 조성물을 제공한다.In addition, the present invention provides a composition for diagnosing pannus of rheumatoid arthritis, including an agent for measuring the expression or activity level of PlGF or VEGF.
또한, 본 발명은 활액에서의 PlGF(placenta growth factor) 발현 또는 활성 수준; 또는 혈청에서의 VEGF(vascular endothelial growth factor) 발현 또는 활성 수준을 확인하는 단계를 포함하는, 류마티스 관절염의 판누스(pannus) 진단을 위한 정보제공방법을 제공한다.In addition, the present invention PlGF (placenta growth factor) expression or activity level in synovial fluid; Or it provides a method for providing information for diagnosing pannus of rheumatoid arthritis, comprising the step of checking the expression or activity level of vascular endothelial growth factor (VEGF) in serum.
또한, 본 발명은 활액에서의 PlGF 발현 또는 활성 수준; 또는 혈청에서의 VEGF 발현 또는 활성 수준을 확인하는 단계를 포함하는, 류마티스 관절염의 판누스(pannus) 진단 방법을 제공한다.In addition, the present invention is the level of PlGF expression or activity in synovial fluid; Or it provides a method for diagnosing pannus of rheumatoid arthritis, comprising the step of confirming the level of VEGF expression or activity in serum.
또한, 본 발명은 상기 PlGF(placenta growth factor) 및 VEGF(vascular endothelial growth factor)로 이루어진 군으로부터 선택되는 하나 이상을 포함하는 바이오마커 조성물의 류마티스 관절염의 판누스(pannus) 진단 용도를 제공한다.In addition, the present invention provides a use of a biomarker composition comprising at least one selected from the group consisting of the placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) for diagnosing pannus of rheumatoid arthritis.
또한, 본 발명은 상기 PlGF(placenta growth factor) 및 VEGF(vascular endothelial growth factor)로 이루어진 군으로부터 선택되는 하나 이상의, 류마티u스 관절염의 판누스(pannus) 진단에 이용되는 바이오마커로서의 용도를 제공한다.In addition, the present invention provides a use as a biomarker used for diagnosing pannus of rheumatoid arthritis, at least one selected from the group consisting of the placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF). do.
본 발명의 일 구현예로서, 상기 PlGF는 활액에서 WBC counts, %호중구, ESR(erythrocyte sedimentation rate), CRP(C reactive protein), GSUS(Grey scale ultrasonography), 및 PDUS(power-Doppler ultrasonography)로 이루어진 군으로부터 선택되는 하나 이상과 양의 상관관계를 가질 수 있다.As an embodiment of the present invention, the PlGF is composed of WBC counts,% neutrophils, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), Gray scale ultrasonography (GSUS), and power-Doppler ultrasonography (PDUS) in synovial fluid. It may have a positive correlation with one or more selected from the group.
본 발명의 다른 구현예로서, 상기 VEGF는 혈청에서 TJC(tender joint count), SJC(swollen joint count), ESR, CRP, DAS 28(disease activity score 28), GSUS, 및 PDUS로 이루어진 군으로부터 선택되는 하나 이상과 양의 상관관계를 가질 수 있다.In another embodiment of the present invention, the VEGF is selected from the group consisting of TJC (tender joint count), SJC (swollen joint count), ESR, CRP, DAS 28 (disease activity score 28), GSUS, and PDUS in serum. It can have a positive correlation with more than one.
본 발명의 또 다른 구현예로서, 상기 활액에서의 PlGF 발현 또는 활성 수준이 정상 대조군에 비해 증가되어 있고, WBC counts, %호중구, ESR, CRP, GSUS, 및 PDUS로 이루어진 군으로부터 선택되는 하나 이상의 수준과 양의 상관관계를 나타낼 경우; 또는 In another embodiment of the present invention, the level of PlGF expression or activity in the synovial fluid is increased compared to the normal control, and at least one level selected from the group consisting of WBC counts,% neutrophils, ESR, CRP, GSUS, and PDUS If it shows a positive correlation with; or
혈청에서의 VEGF 발현 또는 활성 수준이 정상 대조군에 비해 증가되어 있고, TJC, SJC, ESR, CRP, DAS 28, GSUS, 및 PDUS로 이루어진 군으로부터 선택되는 하나 이상의 수준과 양의 상관관계를 나타낼 경우 판누스 증식 정도가 높은 것으로 진단하는 단계를 더 포함할 수 있다.When the level of VEGF expression or activity in serum is increased compared to the normal control, and shows a positive correlation with one or more levels selected from the group consisting of TJC, SJC, ESR, CRP, DAS 28, GSUS, and PDUS It may further include the step of diagnosing that the degree of proliferation is high.
또한, 본 발명은 류마티스 관절염 환자로부터 활액 또는 혈청을 분리하여 후보물질을 처리하는 단계;In addition, the present invention comprises the steps of treating candidate substances by separating synovial fluid or serum from rheumatoid arthritis patients;
상기 후보물질 처리 후 류마티스 관절염 환자의 활액에서의 PlGF 발현 또는 활성 수준, 또는 혈청에서의 VEGF 발현 또는 활성 수준을 확인하는 단계를 포함하는, 류마티스 관절염의 판누스 억제용 물질의 스크리닝 방법을 제공한다.It provides a screening method for a substance for inhibiting pannus of rheumatoid arthritis, comprising the step of confirming the expression or activity level of PlGF in synovial fluid of a patient with rheumatoid arthritis after treatment with the candidate substance, or VEGF expression or activity level in serum.
본 발명의 일 구현예로서, 상기 후보물질 처리 후 류마티스 관절염 환자의 활액에서의 PlGF 발현 또는 활성 수준이 후보물질 처리 전에 비해 감소한 경우; 또는As an embodiment of the present invention, when the expression or activity level of PlGF in the synovial fluid of a patient with rheumatoid arthritis is decreased after treatment with the candidate substance compared to before treatment with the candidate substance; or
혈청에서의 VEGF 발현 또는 활성 수준이 후보물질 처리 전에 비해 감소한 경우, 후보물질을 류마티스 관절염의 판누스 억제용 물질로 선택하는 단계를 더 포함할 수 있다.When the level of VEGF expression or activity in the serum is decreased compared to before treatment with the candidate substance, the step of selecting the candidate substance as a substance for pannus inhibition of rheumatoid arthritis may be further included.
본 발명에 따른 신생혈관형성 관련 인자 PlGF(placenta growth factor) 및 VEGF(vascular endothelial growth factor)는 류마티스 관절염 환자의 활액 및 혈청에서 증가되어 있으며, 활액에서의 PlGF 검출량은 임상적 염증수치, GSUS, 및 PDUS 수준과 유의한 상관관계를 가지고, 혈청에서의 VEGF 검출량은 질병활성도, GSUS, 및 PDUS 수준과 유의한 상관관계를 가지는 것을 확인하였다. 따라서, 본 발명에 따른 PlGF 및 VEGF를 류마티스 관절염의 판누스 진단용 바이오마커로 이용하여 판누스의 증식 정도를 확인함으로써 류마티스 관절염 진단 및 치료제 개발 분야 등에 유용하게 이용할 수 있을 것으로 기대된다.The angiogenesis-related factors PlGF (placenta growth factor) and VEGF (vascular endothelial growth factor) according to the present invention are increased in synovial fluid and serum of rheumatoid arthritis patients, and the amount of PlGF detected in the synovial fluid is clinically inflammatory, GSUS, and It was confirmed that there was a significant correlation with the level of PDUS, and the amount of VEGF detected in the serum had a significant correlation with the level of disease activity, GSUS, and PDUS. Therefore, it is expected that PlGF and VEGF according to the present invention can be usefully used in the field of diagnosing rheumatoid arthritis and developing therapeutic agents by checking the degree of proliferation of pannus using the biomarkers for diagnosing pannus of rheumatoid arthritis.
도 1은 본 발명의 일 구현예에 따른 활막염 비대 및 과맥관질을 보여주는 초음파 검사 결과를 나타낸 것으로, 도 1의 A 및 B는 Grey scale US(GSUS) 이미지, C 및 D는 power-Doppler US(PDUS) 이미지를 나타낸 것이다.
도 2a는 본 발명의 일 구현예에 따른 류마티스 관절염(RA) 환자(n=54) 및 골관절염(OA) 대조군(n=30)의 활액(SF) 내 VEGF, PlGF, sFlt-1, 및 IL-6 농도를 나타낸 도면이다. Bar는 평균 및 SD를 나타낸다.
도 2b는 본 발명의 일 구현예에 따른 RA 환자의 활액 내 VEGF, PlGF, sFlt-1, 및 IL-6 농도의 초음파 검사(US)상 활막염 중증도, 헤모글로빈, ESR, CRP, WBC count 및 %호중구와의 상관관계를 나타낸 도면이다(상단 도면: 상관관계 매트릭스 히트맵(correlation matrix heatmap), 하단 도면: 상관관계 그래프(correlation plot)). *p < 0.05, **p < 0.01, ***p < 0.001.
도 3a는 본 발명의 일 구현예에 따른 GSUS 0-1 RA 환자와 비교하여 GSUS 2-3 RA 환자의 활액 내 VEGF, PlGF, sFlt-1, 및 IL-6 농도를 나타낸 도면이다.
도 3b는 본 발명의 일 구현예에 따른 PDUS 1-3 RA 환자 및 PDUS 0 RA 환자에서의 VEGF, PlGF, sFlt-1, 및 IL-6 농도를 나타낸 도면이다.
도 3c는 본 발명의 일 구현예에 따른 진행성 활막염(active synovitis)을 갖는 RA 환자 및 진행성 활막염을 갖지않는 RA 환자에서의 VEGF, PlGF, sFlt-1, 및 IL-6 농도를 나타낸 도면이다. Bar는 평균 및 SD를 나타낸다. *p < 0.05, **p < 0.01.
도 4a는 본 발명의 일 구현예에 따른 RA 환자(n=157) 및 OA 대조군(n=50)의 혈청 내 VEGF, PlGF, sFlt-1, 및 IL-6 농도를 나타낸 도면이다.
도 4b는 본 발명의 일 구현예에 따른 RA 환자의 혈청 내 VEGF, PlGF, sFlt-1, 및 IL-6 농도와 압통 관절 수(tender joint count), 부종 관절 수(swollen joint count), ESR, CRP, DAS28 및 활막염의 US 점수(GSUS, PDUS) 사이의 상관관계를 나타낸 도면이다.
도 4c는 본 발명의 일 구현예에 따른 활막염 비대의 중증도에 따른 VEGF, PlGF, sFlt-1 및 IL-6의 혈청 내 농도를 나타낸 도면이다.
도 4d는 본 발명의 일 구현예에 따른 맥관질의 정도에 따른 VEGF, PlGF, sFlt-1 및 IL-6의 혈청 내 농도를 나타낸 도면이다.
도 4e는 본 발명의 일 구현예에 따른 진행성 활막염에 따른 VEGF, PlGF, sFlt-1 및 IL-6의 혈청 내 농도를 나타낸 도면이다. Bar는 평균 및 SD를 나타낸다. *p < 0.05, **p < 0.01, ***p < 0.001.1 shows an ultrasound examination result showing synovitis hypertrophy and hypervascularization according to an embodiment of the present invention, in FIG. 1A and B are Gray scale US (GSUS) images, C and D are power-Doppler US ( PDUS) image.
2A is VEGF, PlGF, sFlt-1, and IL- in synovial fluid (SF) of rheumatoid arthritis (RA) patients (n=54) and osteoarthritis (OA) controls (n=30) according to an embodiment of the present invention. 6 is a diagram showing the concentration. Bar represents mean and SD.
2B is an ultrasound examination (US) of VEGF, PlGF, sFlt-1, and IL-6 concentrations in the synovial fluid of an RA patient according to an embodiment of the present invention. It is a diagram showing the correlation with (top view: correlation matrix heatmap, bottom view: correlation plot). *p <0.05, **p <0.01, ***p <0.001.
FIG. 3A is a diagram showing VEGF, PlGF, sFlt-1, and IL-6 concentrations in synovial fluid of GSUS 2-3 RA patients compared to GSUS 0-1 RA patients according to an embodiment of the present invention.
3B is a diagram showing the concentrations of VEGF, PlGF, sFlt-1, and IL-6 in PDUS 1-3 RA patients and
3C is a diagram showing the concentrations of VEGF, PlGF, sFlt-1, and IL-6 in RA patients with active synovitis and RA patients without advanced synovitis according to an embodiment of the present invention. Bar represents mean and SD. *p <0.05, **p <0.01.
4A is a diagram showing the serum levels of VEGF, PlGF, sFlt-1, and IL-6 of RA patients (n=157) and OA control groups (n=50) according to an embodiment of the present invention.
FIG. 4B is a VEGF, PlGF, sFlt-1, and IL-6 concentration in the serum of an RA patient according to an embodiment of the present invention, a tender joint count, a swollen joint count, an ESR, It is a diagram showing the correlation between CRP, DAS28 and US scores (GSUS, PDUS) of synovitis.
4C is a view showing the serum concentrations of VEGF, PlGF, sFlt-1, and IL-6 according to the severity of synovitis hypertrophy according to an embodiment of the present invention.
FIG. 4D is a diagram showing serum concentrations of VEGF, PlGF, sFlt-1, and IL-6 according to the degree of vasculature according to an embodiment of the present invention.
Figure 4e is a view showing the serum concentrations of VEGF, PlGF, sFlt-1, and IL-6 according to advanced synovitis according to an embodiment of the present invention. Bar represents mean and SD. *p <0.05, **p <0.01, ***p <0.001.
본 발명은 PlGF(placenta growth factor) 및 VEGF(vascular endothelial growth factor)로 이루어진 군으로부터 선택되는 하나 이상을 포함하는, 류마티스 관절염의 판누스(pannus) 진단용 바이오마커 조성물을 제공한다.The present invention provides a biomarker composition for diagnosing pannus of rheumatoid arthritis, comprising at least one selected from the group consisting of a placenta growth factor (PlGF) and a vascular endothelial growth factor (VEGF).
본 발명에서 사용되는 용어 "PlGF(placenta growth factor)"는 태반 성장인자로, 인간 혈관 내피 성장 인자 (VEGF) 의 혈소판-유래 성장 인자-유사 영역에 대해 매우 상동성이 있으며, VEGF 와 같이, PlGF 는 시험관내 및 생체내 혈관신생 활성을 갖는다. 본 발명에 있어서, 상기 PlGF는 이를 갖는 동물의 PlGF라면 한정되지 않으며, 예컨대 인간 또는 마우스의 PlGF일 수 있다. 상기 PlGF는 폴리펩타이드 길이 전체를 포함할 수도 있고 이의 단편을 포함할 수도 있다. 바람직하게, 상기 PlGF는 서열번호 1로 표시되는 아미노산 서열(genebank: CAA38698.1)을 포함할 수 있다. The term "PlGF (placenta growth factor)" used in the present invention is a placenta growth factor, and is highly homologous to the platelet-derived growth factor-like region of human vascular endothelial growth factor (VEGF), and like VEGF, PlGF Has angiogenic activity in vitro and in vivo. In the present invention, the PlGF is not limited as long as it is a PlGF of an animal having it, and may be, for example, a human or mouse PlGF. The PlGF may include the entire length of the polypeptide or may include a fragment thereof. Preferably, the PlGF may include an amino acid sequence represented by SEQ ID NO: 1 (genebank: CAA38698.1).
본 발명에서 사용되는 용어 "VEGF(vascular endothelial growth factor)"는 상피성장인자 수용체(epidermal growth factor receptor; EGFR/ErbB)의 일원이다. VEGF는 세포 증식 및 분화를 조절하는 데 필수적인 역할을 하는 것으로 알려져 있다. 구체적으로 세포 외 성장 인자가 결합하면 다른 HER 수용체와 함께 동형- 및/또는 이형이합체로 조립되는 강한 경향성을 갖고, 이는 다양한 형태의 신호 전달 경로 활성화를 초래하여, 세포자멸, 생존, 또는 세포 증식을 유도한다. 본 발명에 있어서, 상기 VEGF는 이를 갖는 동물의 VEGF라면 한정되지 않으며, 예컨대 인간 또는 마우스의 VEGF일 수 있다. 상기 VEGF는 폴리펩타이드 길이 전체를 포함할 수도 있고 이의 단편을 포함할 수도 있다. 바람직하게, 상기 VEGF는 서열번호 2로 표시되는 아미노산 서열(genebank: AAA35789.1)을 포함할 수 있다. The term "vascular endothelial growth factor (VEGF)" used in the present invention is a member of epidermal growth factor receptor (EGFR/ErbB). VEGF is known to play an essential role in regulating cell proliferation and differentiation. Specifically, when the extracellular growth factor binds, it has a strong tendency to assemble into a homo- and/or heterodimer with other HER receptors, which leads to activation of various types of signaling pathways, resulting in apoptosis, survival, or cell proliferation. To induce. In the present invention, the VEGF is not limited as long as it is VEGF of an animal having it, and may be, for example, VEGF of human or mouse. The VEGF may include the entire length of the polypeptide or may include a fragment thereof. Preferably, the VEGF may include an amino acid sequence represented by SEQ ID NO: 2 (genebank: AAA35789.1).
본 발명에서 사용되는 용어 "진단"은 특정 질병 또는 질환에 대한 한 객체의 감수성(susceptibility)을 판정하는 것, 한 객체가 특정 질병 또는 질환을 현재 가지고 있는 지 여부를 판정하는 것, 특정 질병 또는 질환에 걸린 한 객체의 예후(prognosis)를 판정하는 것, 또는 테라메트릭스(therametrics)(예컨대, 치료 효능에 대한 정보를 제공하기 위하여 객체의 상태를 모니터링 하는 것)을 모두 포함하는 의미이다.The term "diagnosis" used in the present invention is to determine the susceptibility of an object to a specific disease or disease, to determine whether an object currently has a specific disease or disease, or to determine whether a specific disease or disease This includes determining the prognosis of an object with disease, or therametrics (eg, monitoring the condition of an object to provide information on treatment efficacy).
본 발명에서 사용되는 용어 "바이오마커(biomarker)"는 단백질이나 DNA, RNA, 대사물질 등을 이용해 몸 안의 변화를 알아낼 수 있는 지표를 의미하고, 바이오마커를 활용하면 생명체의 정상 또는 병리적인 상태, 약물에 대한 반응 정도 등을 객관적으로 측정할 수 있다. 암을 비롯해 뇌졸증, 치매 등 각종 난치병을 진단하는데 바이오마커가 활용되고 있으며, 본 발명에 있어서는 류마티스 관절염 또는 류마티스 관절염의 판누스를 진단하는데 이용될 수 있다. 또한, 신약개발과정에서 바이오마커를 활용할 수 있고, 이를 통해서 신약의 안전성을 확보할 수 있고 신약 개발 과정에서 소요되는 비용을 절감할 수 있는 효과도 얻을 수 있다.The term "biomarker" used in the present invention refers to an index that can detect changes in the body using proteins, DNA, RNA, metabolites, etc., and when using a biomarker, the normal or pathological state of an organism, The degree of reaction to drugs can be objectively measured. Biomarkers are used to diagnose various incurable diseases such as cancer, stroke, and dementia, and in the present invention, they can be used to diagnose pannus of rheumatoid arthritis or rheumatoid arthritis. In addition, biomarkers can be used in the new drug development process, and through this, the safety of the new drug can be secured, and the effect of reducing the cost required in the new drug development process can also be obtained.
또한, 본 발명은 상기 PlGF 또는 VEGF의 발현 또는 활성 수준을 측정하는 제제를 포함하는, 류마티스 관절염의 판누스(pannus) 진단용 조성물을 제공한다.In addition, the present invention provides a composition for diagnosing pannus of rheumatoid arthritis, including an agent for measuring the expression or activity level of PlGF or VEGF.
본 발명에 있어서, 상기 "PlGF 또는 VEGF의 발현 또는 활성 수준을 측정하는 제제"는 PlGF 또는 VEGF의 단백질 또는 이를 코딩하는 mRNA에 특이적으로 결합하여, PlGF 또는 VEGF의 발현 또는 활성 수준을 확인함으로써 PlGF 또는 VEGF의 검출에 사용될 수 있는 물질을 의미한다. 예컨대, PlGF 또는 VEGF에 특이적으로 결합하는 항체, 앱타머, 리간드, PNA(peptide nucleic acid), 올리고펩티드, 안티센스 올리고뉴클레오티드, 프라이머 쌍 또는 프로브일 수 있으나, 이에 제한되는 것은 아니다. In the present invention, the "agent for measuring the expression or activity level of PlGF or VEGF" is PlGF by specifically binding to the protein of PlGF or VEGF or the mRNA encoding it, and confirming the expression or activity level of PlGF or VEGF Or it means a substance that can be used for the detection of VEGF. For example, it may be an antibody, an aptamer, a ligand, a peptide nucleic acid (PNA), an oligopeptide, an antisense oligonucleotide, a primer pair, or a probe that specifically binds to PlGF or VEGF, but is not limited thereto.
본 발명에서 사용되는 용어 "항체"는 항원에 특이적으로 결합하여 인식하는 면역글로불린 유전자 또는 이의 단편에서 유래하는 프레임워크 영역을 포함하는 폴리펩티드를 의미한다. 인식된 면역글로불린 유전자는 카파, 람다, 알파, 감마, 델타, 엡실론, 및 뮤 불변 영역 유전자를 비롯하여, 무수한 면역글로불린 가변 영역 유전자를 포함한다. 경쇄는 카파 또는 람다로 분류되며, 중쇄는 감마, 뮤, 알파, 델타, 또는 엡실론으로 분류되고, 결과적으로 각각 면역글로불린 부류 IgG, IgM, IgA, IgD 및 IgE를 한정한다. 전형적으로, 항체의 항원-결합 영역은 결합 특이성 및 친화성에서 가장 핵심적이게 된다. 일부 실시형태에서, 항체 또는 항체의 단편은 인간, 마우스, 래트, 햄스터, 토끼, 낙타 등을 포함한, 상이한 유기체에서 유래될 수 있다.The term "antibody" as used herein refers to a polypeptide comprising a framework region derived from an immunoglobulin gene or fragment thereof that is specifically recognized by binding to an antigen. Recognized immunoglobulin genes include a myriad of immunoglobulin variable region genes, including kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes. Light chains are classified as kappa or lambda, heavy chains are classified as gamma, mu, alpha, delta, or epsilon, consequently defining the immunoglobulin classes IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody becomes paramount in binding specificity and affinity. In some embodiments, the antibody or fragment of an antibody may be derived from different organisms, including humans, mice, rats, hamsters, rabbits, camels, and the like.
본 발명에서 사용되는 용어 "앱타머(aptamer)"는 올리고뉴클레오타이드 물질로서, 그 자체로 안정된 삼차구조를 가지면서 표적분자에 높은 친화성과 특이성으로 결합할 수 있는 특징을 가진 단일가닥 핵산(DNA, RNA 또는 변형핵산)을 의미하며, 화학적으로 합성이 가능하고 열과 pH 변화에 대하여 비교적으로 유연한 특징을 가지고 있고, SELEX(Systematic Evolution of Ligands of Exponential enrichment)라는 방법으로 원하는 다양한 목적 물질 (단백질, 펩타이드, 지질, 무기 화합물, 저분자 유기물질, 당, 염색물질, DNA, 금속이온, 세포, 항생제 등)에 대한 앱타머를 개발할 수 있다.The term "aptamer" used in the present invention is an oligonucleotide material, a single-stranded nucleic acid (DNA, RNA) having a stable tertiary structure by itself and capable of binding to a target molecule with high affinity and specificity. Or modified nucleic acid), can be chemically synthesized, has comparatively flexible characteristics against heat and pH changes, and is a method called SELEX (Systematic Evolution of Ligands of Exponential enrichment), which is used for various target substances (proteins, peptides, lipids). , Inorganic compounds, low molecular weight organic substances, sugars, dyeing substances, DNA, metal ions, cells, antibiotics, etc.) can be developed.
본 발명에 있어서, 상기 "PlGF 또는 VEGF의 발현 또는 활성 수준을 측정"하는 것은 류마티스 관절염의 판누스를 진단하기 위하여 시료에서 PlGF 또는 VEGF 단백질 또는 이를 코딩하는 mRNA의 존재 여부와 발현 정도 또는 활성 정도를 확인하는 과정일 수 있으며, 예컨대 상기 PlGF 또는 VEGF 단백질 또는 이를 코딩하는 mRNA에 대하여 특이적으로 결합하는 분자를 이용하여 단백질 또는 이를 코딩하는 mRNA의 양 또는 활성 수준을 확인하는 방법이 적용될 수 있다. In the present invention, the "measurement of the expression or activity level of PlGF or VEGF" is to determine the presence and expression level or activity level of PlGF or VEGF protein or mRNA encoding the same in a sample in order to diagnose pannus of rheumatoid arthritis. It may be a process of identification, and for example, a method of confirming the amount or activity level of the protein or the mRNA encoding the PlGF or VEGF protein or mRNA encoding the same may be applied using a molecule that specifically binds to it.
본 발명에 있어서, 상기 PlGF 또는 VEGF의 발현 또는 활성 수준은 종래에 개발된 다양한 정량적 또는 정성적 면역분석 프로토콜에 따라 확인할 수 있다. 예컨대, 상기 면역분석 포맷은 효소면역분석법(ELISA), 방사능면역분석법(radioimmnoassay, RIA), 샌드위치 측정법(sandwich assay), 웨스턴 블롯팅, 면역침강법, 면역조직화학염색법(immnohistochemical staining), 유체 세포 측정법(flow cytometry), 형광활성화 세포분류법(FACS), 효소기질발색법 및 항원-항체 응집법을 포함한다. 본 발명의 일 구현예에 따르면 효소면역분석법(ELISA)을 이용하여 PlGF 또는 VEGF의 발현 또는 활성 수준을 확인할 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the expression or activity level of PlGF or VEGF can be confirmed according to various quantitative or qualitative immunoassay protocols developed in the prior art. For example, the immunoassay format is enzyme immunoassay (ELISA), radioimmunoassay (RIA), sandwich assay, western blotting, immunoprecipitation, immunohistochemical staining, fluid cytometry (flow cytometry), fluorescence activated cell sorting (FACS), enzyme substrate coloring, and antigen-antibody aggregation method. According to an embodiment of the present invention, the expression or activity level of PlGF or VEGF may be confirmed using an enzyme immunoassay (ELISA), but is not limited thereto.
또한, 본 발명은 활액에서의 PlGF(placenta growth factor) 발현 또는 활성 수준; 또는 혈청에서의 VEGF(vascular endothelial growth factor) 발현 또는 활성 수준을 확인하는 단계를 포함하는, 류마티스 관절염의 판누스(pannus) 진단을 위한 정보제공방법을 제공한다.In addition, the present invention PlGF (placenta growth factor) expression or activity level in synovial fluid; Or it provides a method for providing information for diagnosing pannus of rheumatoid arthritis, comprising the step of checking the expression or activity level of vascular endothelial growth factor (VEGF) in serum.
또한, 본 발명은 활액에서의 PlGF 발현 또는 활성 수준; 또는 혈청에서의 VEGF 발현 또는 활성 수준을 확인하는 단계를 포함하는, 류마티스 관절염의 판누스(pannus) 진단 방법을 제공한다.In addition, the present invention is the level of PlGF expression or activity in synovial fluid; Or it provides a method for diagnosing pannus of rheumatoid arthritis, comprising the step of confirming the level of VEGF expression or activity in serum.
본 발명에 있어서, 상기 방법은 활액에서의 PlGF 발현 또는 활성 수준이 정상 대조군에 비해 증가되어 있고, WBC counts, %호중구, ESR, CRP, GSUS, 및 PDUS로 이루어진 군으로부터 선택되는 하나 이상의 수준과 양의 상관관계를 나타낼 경우; 또는 In the present invention, the method is that the level of PlGF expression or activity in synovial fluid is increased compared to the normal control, and at least one level and amount selected from the group consisting of WBC counts,% neutrophils, ESR, CRP, GSUS, and PDUS If it shows a correlation of; or
혈청에서의 VEGF 발현 또는 활성 수준이 정상 대조군에 비해 증가되어 있고, TJC, SJC, ESR, CRP, DAS 28, GSUS, 및 PDUS로 이루어진 군으로부터 선택되는 하나 이상의 수준과 양의 상관관계를 나타낼 경우 판누스 증식 정도가 높은 것으로 진단하는 단계를 더 포함할 수 있다.When the level of VEGF expression or activity in serum is increased compared to the normal control, and shows a positive correlation with one or more levels selected from the group consisting of TJC, SJC, ESR, CRP, DAS 28, GSUS, and PDUS It may further include the step of diagnosing that the degree of proliferation is high.
본 발명에서 사용되는 용어 "상관관계"는 두 변량 중 한 쪽이 증가함에 따라 다른 한 쪽이 증가 또는 감소할 때 두 변량의 관계를 의미한다. 한 쪽이 증가함에 따라 다른 한 쪽이 증가하는 경우 양의 상관관계, 한 쪽이 증가함에 따라 다른 한 쪽이 감소하는 경우 음의 상관관계라고 한다.The term "correlation" as used in the present invention refers to a relationship between two variables when one of the two variables increases or decreases as the other increases or decreases. When one side increases as the other increases, it is called a positive correlation, and when one side increases and the other decreases, it is called a negative correlation.
본 발명에 있어서, PlGF는 류마티스 관절염 환자의 활액에서 발현 또는 활성 수준이 증가하며, 상기 PlGF의 발현 또는 활성 수준이 증가함에 따라 활액에서의 (white blood cell(WBC) counts), %호중구, ESR(erythrocyte sedimentation rate), CRP(C reactive protein), GSUS(Grey scale ultrasonography), 및 PDUS(power-Doppler ultrasonography)로 이루어진 군으로부터 선택되는 하나 이상의 수준이 증가하여 PlGF와 양의 상관관계를 가질 수 있다. In the present invention, PlGF is expressed or active level in the synovial fluid of a patient with rheumatoid arthritis increases, and as the expression or activity level of PlGF increases, (white blood cell (WBC) counts),% neutrophils, ESR ( At least one level selected from the group consisting of erythrocyte sedimentation rate), CRP (C reactive protein), GSUS (Grey scale ultrasonography), and PDUS (power-Doppler ultrasonography) may have a positive correlation with PlGF.
또한, VEGF는 류마티스 관절염 환자의 혈청에서 발현 또는 활성 수준이 증가하며, 상기 VEGF의 발현 또는 활성 수준이 증가함에 따라 혈청에서의 TJC(tender joint count), SJC(swollen joint count), ESR, CRP, DAS 28(disease activity score 28), GSUS, 및 PDUS로 이루어진 군으로부터 선택되는 하나 이상의 수준이 증가하여 VEGF와 양의 상관관계를 가질 수 있다.In addition, the expression or activity level of VEGF increases in the serum of patients with rheumatoid arthritis, and as the expression or activity level of VEGF increases, the serum TJC (tender joint count), SJC (swollen joint count), ESR, CRP, At least one level selected from the group consisting of DAS 28 (disease activity score 28), GSUS, and PDUS may be increased to have a positive correlation with VEGF.
본 발명에 있어서, 상기 "판누스의 증식"은 활막에 염증이 있다고도 표현하는데, 이를 활막염(synovitis)이라고 한다. 이 활막염의 중증도(severity)를 측정함에 있어서 초음파(ultrasonography, US)를 이용할 수 있으며, 예컨대 GSUS(Grey scale ultrasonoraphy)를 이용하여 활막염의 중증도, 즉 판누스의 증식 정도를 나타낼 수 있다. 또한, 도플러 효과를 이용하여 유체의 흐름을 추가 확인할 수 있는 PDUS(power-Doppler ultrasonography)는 증식된 활막에서 혈관형성 정도를 나타낼 수 있다.In the present invention, the "proliferation of pannus" is also expressed as inflammation of the synovial membrane, which is called synovitis. In measuring the severity of the synovitis, ultrasound (ultrasonography, US) may be used, and, for example, the severity of synovitis, that is, the degree of pannus proliferation, may be indicated by using a gray scale ultrasonoraphy (GSUS). In addition, power-Doppler ultrasonography (PDUS), which can additionally check the flow of fluid using the Doppler effect, can indicate the degree of angiogenesis in the proliferated synovial membrane.
또한, 본 발명은 류마티스 관절염 환자로부터 활액 또는 혈청을 분리하여 후보물질을 처리하는 단계; 및In addition, the present invention comprises the steps of treating candidate substances by separating synovial fluid or serum from rheumatoid arthritis patients; And
상기 후보물질 처리 후 류마티스 관절염 환자의 활액에서의 PlGF 발현 또는 활성 수준, 또는 혈청에서의 VEGF 발현 또는 활성 수준을 확인하는 단계를 포함하는, 류마티스 관절염의 판누스 억제용 물질의 스크리닝 방법을 제공한다.It provides a screening method for a substance for inhibiting pannus of rheumatoid arthritis, comprising the step of confirming the expression or activity level of PlGF in synovial fluid of a patient with rheumatoid arthritis after treatment with the candidate substance, or VEGF expression or activity level in serum.
본 발명에서 사용되는 용어 “후보물질”은 류마티스 관절염 환자의 판누스 억제 여부를 확인하기 위하여 스크리닝에 사용되는 미지의 물질을 의미하며, 본 발명의 일 구현예에 따르면, 상기 류마티스 관절염 판누스 억제용 후보물질은 뉴클레오티드, DNA, RNA, 아미노산, 앱타머, 단백질, 화합물, 천연물, 및 천연추출물로 이루어진 군으로부터 선택되는 하나 이상일 수 있으나, 이에 제한은 없다.The term "candidate" used in the present invention refers to an unknown substance used for screening to determine whether pannus is suppressed in rheumatoid arthritis patients, and according to an embodiment of the present invention, for inhibiting pannus of rheumatoid arthritis The candidate material may be one or more selected from the group consisting of nucleotides, DNA, RNA, amino acids, aptamers, proteins, compounds, natural products, and natural extracts, but is not limited thereto.
본 발명에 있어서, 상기 후보물질 처리 후 류마티스 관절염 환자의 활액에서의 PlGF 발현 또는 활성 수준이 후보물질 처리 전에 비해 감소한 경우; 또는In the present invention, when the level of PlGF expression or activity in synovial fluid of a patient with rheumatoid arthritis after treatment with the candidate substance is decreased compared to before treatment with the candidate substance; or
혈청에서의 VEGF 발현 또는 활성 수준이 후보물질 처리 전에 비해 감소한 경우, 후보물질을 류마티스 관절염의 판누스 억제용 물질로 선택하는 단계를 더 포함할 수 있다.When the level of VEGF expression or activity in the serum is decreased compared to before treatment with the candidate substance, the step of selecting the candidate substance as a substance for pannus inhibition of rheumatoid arthritis may be further included.
본 발명의 일 실험예에서는 활막세포에서 주로 분비되는 혈관신생유발 인자인 PlGF 및 IL-6 수준이 RA 환자의 SF에서 증가되어 있으며, PlGF 및 IL-6 수준과 전신 염증 반응을 나타내는 마커인 혈액 내 ESR 및 CRP 수준, SF 내 WBC counts 및 %호중구, 판누스의 증식 정도를 나타내는 GSUS 및 혈관형성 정도를 나타내는 PDUS의 상관관계를 확인함으로써, PlGF 및 IL-6 수준과 RA 환자에서의 활막염 중증도 및 전신 염증 반응이 상관관계를 가지는 것을 확인하였다(실험예 1 참조).In one experimental example of the present invention, the levels of PlGF and IL-6, which are angiogenesis-inducing factors secreted mainly from synovial cells, are increased in the SF of RA patients, and the levels of PlGF and IL-6 and in the blood, which are markers for systemic inflammatory response By confirming the correlation between ESR and CRP levels, WBC counts in SF and GSUS, which represents the degree of proliferation of neutrophils and pannus, and PDUS, which represents the degree of angiogenesis, PlGF and IL-6 levels and synovitis severity and systemic in RA patients It was confirmed that the inflammatory response had a correlation (see Experimental Example 1).
본 발명의 다른 실험예에서는 VEGF 및 IL-6 수준이 RA 환자의 혈청에서 증가되어 있으며, VEGF 및 IL-6 수준과 TJC, SJC, ESR, CRP 및 DAS28 점수, GSUS 및 PDUS의 상관관계를 확인함으로써, 상기 VEGF 및 IL-6의 혈청 수준이 활막 증식 및 초음파 검사(US) 상 과맥관질(hyper-vascularity)을 나타내는 것을 확인하였다(실험예 2 참조).In another experimental example of the present invention, VEGF and IL-6 levels are increased in the serum of RA patients, and by confirming the correlation between VEGF and IL-6 levels and TJC, SJC, ESR, CRP and DAS28 scores, GSUS and PDUS , It was confirmed that the serum levels of VEGF and IL-6 showed synovial proliferation and hyper-vascularity on ultrasound (US) (see Experimental Example 2).
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, a preferred embodiment is presented to aid the understanding of the present invention. However, the following examples are provided for easier understanding of the present invention, and the contents of the present invention are not limited by the following examples.
실시예Example 1. One. 활액Synovial fluid 및 혈청 채취 And serum collection
류마티스 관절염(RA) 환자(n=157)는 2010 ACR/EULAR RA 분류 기준을 충족하였다. 활액(synovial fluid, 이하 SF) 시료는 부은 관절(swollen joint)에 대한 관절강세정술(arthrocentesis)을 시술받은 RA 환자(n=54) 및 골관절염(osteoarthritis, OA) 대조군(n=30)으로부터 채취하였으며, 상기 관절강세정술을 시술받은 RA 환자들의 특징을 하기 표 1에 나타내었다.Patients with rheumatoid arthritis (RA) (n=157) met the 2010 ACR/EULAR RA classification criteria. Synovial fluid (SF) samples were collected from RA patients (n=54) and osteoarthritis (OA) controls (n=30) who underwent arthrocentesis for swollen joints. , The characteristics of RA patients undergoing the articular cavity cleaning are shown in Table 1 below.
상기 표 1에서 데이터는 연속 변수에 대한 평균(표준편차) 또는 중앙값(interquartile range)으로 표시된다. RF: 류마티스성 인자(rheumatoid factor), ACPA: 항-시트룰린화 펩티드 항체(anti-citrullinated peptide antibodies), WBC: 백혈구(white blood cell), ESR: 적혈구 침강 속도(erythrocyte sedimentation rate), CRP: C-반응성 단백질(C-reactive protein), SF: 활액(synovial fluid), PD: prednisone, GSUS: grey scale ultrasound, PDUS: power Doppler ultrasound.In Table 1, data are expressed as mean (standard deviation) or median (interquartile range) for continuous variables. RF: rheumatoid factor, ACPA: anti-citrullinated peptide antibodies, WBC: white blood cells, ESR: erythrocyte sedimentation rate, CRP: C- C-reactive protein, SF: synovial fluid, PD: prednisone, GSUS: gray scale ultrasound, PDUS: power Doppler ultrasound.
혈청 시료 역시 연구 개시시점에서 RA 환자(n=157) 및 OA 대조군(n=50)으로부터 채취하였다. 157명의 RA 환자 중에서, 중등도(moderate) 또는 중증(high)의 질병활성도를 갖는 환자는 103명, 낮은 질병활성도를 갖는 환자는 54명으로 분류되었고, 이들의 특징을 하기 표 2에 나타내었다. Serum samples were also taken from RA patients (n=157) and OA controls (n=50) at the start of the study. Among the 157 RA patients, 103 patients with moderate or high disease activity and 54 patients with low disease activity were classified, and their characteristics are shown in Table 2 below.
DA: 질병활성도(disease activity), BMI: 체질량 지수(body mass index)본 발명은 가톨릭대학교 병원 임상연구심의위원회로부터 승인 받았으며(No.KC14TIMI0697), 연구 참여자로부터 서면으로 동의를 받았다.DA: disease activity, BMI: body mass index The present invention was approved by the Catholic University Hospital Institutional Review Board (No.KC14TIMI0697), and consent was obtained in writing from the study participants.
실시예Example 2. 2. VEGFVEGF , , PlGFPlGF , , sFltsFlt -1 및 IL-6 측정-1 and IL-6 measurements
증식하는 활막세포에서 주로 분비되는 주요한 혈관신생 유발인자인 VEGF, PlGF 및 IL-6의 농도를 RA 및 OA 환자의 SF 및 혈청에서 알려진 방법(Yoo SA, Kim M, Kang MC, et al. Nat Immunol 2019;20:1348-59.)에 따라 ELISA(enzyme-linked immunosorbent assay)로 측정하였다. 대조군으로, 활막세포에서 생산되는 항-혈관신생 분자인 sFlt-1의 수준을 동일 시료에 대하여 ELISA로 측정하였다. ELISA의 VEGF, PlGF, IL-6 및 sFlt-1 검출한계는 10 pg/ml이었다.The concentration of VEGF, PlGF, and IL-6, the major angiogenesis inducers secreted mainly from proliferating synovial cells, was determined in SF and serum of RA and OA patients (Yoo SA, Kim M, Kang MC, et al. Nat Immunol). 2019;20:1348-59.), measured by enzyme-linked immunosorbent assay (ELISA). As a control, the level of sFlt-1, an anti-angiogenic molecule produced in synovial cells, was measured by ELISA for the same sample. The detection limits of VEGF, PlGF, IL-6 and sFlt-1 by ELISA were 10 pg/ml.
실시예Example 3. 활막염 중증도( 3. Synovitis severity ( synovitissynovitis severity) 평가를 위한 관절의 초음파 검사 평가 severity) evaluation of ultrasound examination of joints for evaluation
상기 실시예 1에서 SF 시료를 채취한 RA 환자(n=54)에 대하여 근골격계 초음파 검사(US)를 실시하였다. 추가적으로, 연구 개시시점에서 관절강세정술 및/또는 관절 내 스테로이드 주사가 필요한 명확한 관절 종창 및 압통을 가진 RA 환자(n=68)의 경우, 혈액을 채취할 때 관절에 대한 초음파 검사 역시 실시하였다. 활막염(synovitis) 점수는 도 1에 나타낸 Grey scale US(GSUS) (도 1의 A 및 B) 및 power-Doppler US(PDUS) (도 1의 C 및 D) 이미지로 결정하였다. 이 때 GSUS 이미지는 근위지간(proximal interphalangeal, PIP) 관절 내 활막염 비대를 나타내며, PDUS 이미지는 PIP 관절 내 활막의 과맥관질을 나타낸다. GSUS 점수(0-3 range)는 다음과 같이 활막 비대(synovial hypertrophy)의 정도에 따라 정의하였다: grade 0 = 활막 비대 없음, grade 1 = 최소 활막 비대, grade 2 = 중등도(moderate) 활막 비대, 및 grade 3 = 중증(severe) 활막 비대. PDUS 점수는(0-3 range) 다음과 같이 관절의 활막 내 맥관질(vascularity)의 정도로 평가하였다: grade 0 = Doppler 활성 없음, grade 1 = 최소 Doppler 활성, grade 2 = 중등도(moderate) Doppler 활성(background 활막의 <50%), 및 grade 3 = 중증(severe) Doppler 활성 (background 활막의 >50%). GSUS가 ≥2이거나, PDUS가 ≥1인 경우, 진행성(active) 활막염을 갖는 환자로 고려하였다.The musculoskeletal ultrasound (US) was performed on RA patients (n=54) who took SF samples in Example 1. In addition, in the case of RA patients (n=68) with definite joint swelling and tenderness requiring arthroplasty and/or intra-articular steroid injection at the start of the study, ultrasound of the joint was also performed when blood was collected. The synovitis score was determined by the Gray scale US (GSUS) (A and B of FIG. 1) and power-Doppler US (PDUS) (C and D of FIG. 1) images shown in FIG. 1. In this case, the GSUS image represents an enlarged synovitis in the proximal interphalangeal (PIP) joint, and the PDUS image represents the hypervascularization of the synovial membrane in the PIP joint. The GSUS score (range 0-3) was defined according to the degree of synovial hypertrophy as follows:
실시예Example 4. 임상 파라미터 평가 4. Evaluation of clinical parameters
RA 환자의 ESR과 CRP 수준, 압통 관절 수(tender joint count, TJC) 및 부종 관절 수(swollen joint count, SJC)를 연구 개시시점과 그 이후에 측정하였다. 상기 TJC는 관절의 통증을, SJC는 붓기를 의미한다. 또한, 기존에 혈액에서 측정되던 염증 수치인 ESR 및 CRP 수준도 함께 검토되었으며, 이에 더하여 류마티스 인자(rheumatoid factor, RF) 및 ACPA(anti-citrullinated peptide antibodies)를 포함하는 혈청학적 마커에 대한 데이터를 얻었다. 손과 발에 대한 방사선 촬영 검사를 실시하여, 관절열극(joint space)의 좁은 정도와 침식 정도를 van der Heijde-modified Sharp score (vdH Sharp score)에 따라 점수화 하였다. RA 환자의 질병활성도를 질환(disease) 활성도(activity) 점수 28ESR (DAS28ESR)에 기초하여 결정하였다: DAS28≤3.2 = 낮은 질병활성도; DAS28>3.2 = 중등도(moderate) 또는 중증(high) 질병활성도. ESR and CRP levels, tender joint count (TJC) and swollen joint count (SJC) in RA patients were measured at the start of the study and after. The TJC means joint pain and SJC means swelling. In addition, ESR and CRP levels, which were previously measured levels of inflammation in blood, were also reviewed, and in addition, data on serological markers including rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) were obtained. . Radiographic examination of the hands and feet was performed, and the degree of narrowing and erosion of the joint space were scored according to the van der Heijde-modified Sharp score (vdH Sharp score). The disease activity of RA patients was determined based on a disease activity score of 28 ESR (DAS28 ESR ): DAS28≦3.2 = low disease activity; DAS28>3.2 = moderate or high disease activity.
실시예Example 5. 통계 분석 5. Statistical Analysis
연속 변수의 비교를 student’s unpaired t 테스트 또는 Mann-Whitney U 테스트로 조사하였으며, 범주형 변수의 비교를 Chi-Square 테스트 또는 Fisher’s exact 테스트로 조사하였다. 두 변수 사이의 상관관계를 Pearson’s correlation 테스트로 분석하였다. 동일 대상에서 연구 개시시점과 그 이후의 측정 값 사이의 차이를 조사하기 위하여 paired t test를 적용하였다. 통계 분석은 IBM SPSS Statistics 20 (IBM Corp., Armonk, NY, USA)을 사용하여 실시하였고, 그래프는 GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA)를 사용하여 그렸다. 히트맵 상관관계 이미지(heatmap correlation image)는 R software 3.5.1 (R Project, Vienna, Austria)의 package ‘corrplot’를 사용하여 얻었다.The comparison of continuous variables was investigated by the student's unpaired t test or the Mann-Whitney U test, and the comparison of categorical variables was investigated by the Chi-Square test or Fisher's exact test. The correlation between the two variables was analyzed by Pearson's correlation test. The paired t test was applied to investigate the difference between the starting point of the study and the measured values thereafter in the same subject. Statistical analysis was performed using IBM SPSS Statistics 20 (IBM Corp., Armonk, NY, USA), and graphs were drawn using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). The heatmap correlation image was obtained using the package “corrplot” of R software 3.5.1 (R Project, Vienna, Austria).
실험예Experimental example 1. One. PlGFPlGF 및 IL-6 수준과 RA And IL-6 levels and RA 환자에서의In the patient 활막염 중증도 및 전신 염증 반응의 상관관계 확인 Confirmation of correlation between synovitis severity and systemic inflammatory response
RA 환자의 SF 내 VEGF, PlGF, sFlt-1 및 IL-6 농도는 도 2a에 나타낸 바와 같이 OA 대조군에 비하여 유의성 있게 높은 것을 확인하였다. 또한, 활막세포에서 주로 분비되는 혈관신생유발 사이토카인인 VEGF, PlGF 및 IL-6 수준이 RA 환자에서 국소 및/또는 전신 염증 반응을 나타내는지 테스트 한 결과, 도 2b 및 상기 표 1에 나타난 바와 같이, SF(n=54) 내 PlGF 농도는 RA에서 전신 염증 반응을 나타내는 마커인 혈액 내 ESR 및 CRP 수준뿐만 아니라, SF 내 WBC counts(r = 0.466 and p = 0.001) 및 %호중구와 상관관계를 나타내었다. 대조군으로 사용한 항-혈관신생 단백질인 sFlt-1의 수준 또한 혈액 내 염증성 마커와 양의 상관관계를 나타내었다(ESR: r = 0.364, p = 0.007; CRP: r = 0.496, p <0.001). 그러나, SF 내 VEGF와 IL-6 수준은 SF 내 WBC counts 및 %호중구와 양의 상관관계를 보였지만, ESR 및 CRP와는 상관관계를 보이지 않았다.It was confirmed that the concentrations of VEGF, PlGF, sFlt-1, and IL-6 in SF of RA patients were significantly higher than those of the OA control group, as shown in FIG. 2A. In addition, as a result of testing whether the levels of VEGF, PlGF, and IL-6, which are angiogenesis-inducing cytokines mainly secreted from synovial cells, exhibit local and/or systemic inflammatory responses in RA patients, as shown in FIG. 2B and Table 1 above. , PlGF concentration in SF (n=54) was correlated with ESR and CRP levels in blood, which are markers of systemic inflammatory response in RA, as well as WBC counts (r = 0.466 and p = 0.001) and% neutrophils in SF. I got it. The level of sFlt-1, an anti-angiogenic protein used as a control, also showed a positive correlation with inflammatory markers in blood (ESR: r = 0.364, p = 0.007; CRP: r = 0.496, p <0.001). However, VEGF and IL-6 levels in SF showed a positive correlation with WBC counts and% neutrophils in SF, but not with ESR and CRP.
다음으로, 혈관신생유발 사이토카인이 RA 환자에서 초음파 검사(US)로 결정한 활막염 중증도를 반영하는지 알아보았다. 그 결과, 도 3a에 나타낸 바와 같이 SF 내 PlGF 및 IL-6 농도는 GSUS 상 중증도에서 중증 활막염 비대(grade 2 및 3)를 갖는 환자에서 활막 비대가 없거나 약한(mild) 활막 비대(grade 0 및 1)를 갖는 환자에 비하여 높았다. 또한, PDUS 검사 결과, 도 3b에 나타낸 바와 같이 PlGF 농도는 증가된 맥관질(vascularity, grade 1 to 3)을 갖는 환자에서 그렇지 않은 환자(grade 0)에 비하여 높았으나, 다음 세 분자들은 증가된 맥관질에 따른 유의한 차이를 보이지 않았다. 진행성 활막염의 존재를 기준(GSUS ≥2 또는 PDUS ≥1)으로 환자를 두 그룹으로 분류한 경우, 도 3c에 나타낸 바와 같이 VEGF와 sFlt-1은 아니었지만, PlGF 및 IL-6 수준은 비진행성 활막염을 갖는 환자에 비하여 진행성 활막염을 갖는 환자에서 상당히 높은 것을 확인할 수 있었다.Next, we examined whether angiogenesis-inducing cytokines reflect the severity of synovitis determined by ultrasound (US) in RA patients. As a result, as shown in Fig. 3a, the concentration of PlGF and IL-6 in SF was not or had mild synovial hypertrophy (
종합하면, 상기와 같은 결과는 활막세포에서 주로 분비되는 혈관신생유발 인자인 PlGF 및 IL-6 수준이 RA 환자의 SF에서 증가되어 있으며, RA 환자의 국소 및 전신 염증 상태뿐만 아니라 활막염 중증도를 나타냄을 보여준다.Taken together, the above results indicate that the levels of PlGF and IL-6, angiogenesis-inducing factors secreted mainly from synovial cells, are increased in SF of RA patients, indicating the severity of synovitis as well as local and systemic inflammatory conditions in RA patients. Show.
실험예Experimental example 2. 2. VEGFVEGF 및 IL-6의 And of IL-6 순환성Circularity 수준과 RA의 질병활성도 및 중증도의 상관관계 확인 Confirmation of correlation between level and disease activity and severity of RA
낮은 질병활성도를 갖는 54명의 환자 및 중등도 또는 중증 질병활성도를 갖는 103명의 환자로 구성된 총 157명의 RA 환자로부터 상기 실시예 1과 같이 혈청 시료를 채취하였으며, 연구 개시시점에서의 의료정보(demographic) 및 질환 특성을 상기 표 2에 나타내었다. 먼저, 혈청 VEGF, PlGF, sFlt-1 및 IL-6 농도를 확인한 결과, 도 4a에 나타낸 바와 같이 RA 환자에서 상기 인자들의 농도가 증가되어 있음을 확인하였다. 또한, RA 질병활성도에 대한 파라미터와 달리, 도 4b에 나타낸 바와 같이 VEGF 및 IL-6 수준은 TJC, SJC, ESR, CRP 및 DAS28 점수와 상관관계를 보였다. Serum samples were collected as in Example 1 from a total of 157 RA patients consisting of 54 patients with low disease activity and 103 patients with moderate or severe disease activity. The disease characteristics are shown in Table 2 above. First, as a result of checking the serum VEGF, PlGF, sFlt-1, and IL-6 concentrations, it was confirmed that the concentration of the above factors was increased in RA patients as shown in FIG. 4A. In addition, unlike parameters for RA disease activity, VEGF and IL-6 levels were correlated with TJC, SJC, ESR, CRP and DAS28 scores as shown in FIG. 4B.
추가적으로, 도 4b의 히트맵 및 상관관계 플롯에 나타난 바와 같이, 혈청 VEGF 및 IL-6는 GSUS 및 PDUS 점수 모두와 양의 상관관계를 보였다. 더욱이, 혈청 VEGF 및 IL-6 농도는 도 4c에 나타낸 GSUS 상 중등도에서 중증 활막 비대를 갖는 환자 및 도 4d에 나타낸 PDUS 상 증가된 맥관질을 갖는 환자에서 그렇지 않은 환자에 비하여 높았으며, 혈청 VEGF 및 IL-6 농도는 도 4e에 나타낸 바와 같이 진행성 활막염과 유의성 있게 관련성을 보였다.Additionally, as shown in the heat map and correlation plot of FIG. 4B, serum VEGF and IL-6 showed a positive correlation with both GSUS and PDUS scores. Moreover, serum VEGF and IL-6 concentrations were higher in patients with moderate to severe synovial hypertrophy on GSUS as shown in FIG. 4C and in patients with increased vasculature on PDUS as shown in FIG. IL-6 concentration showed a significant correlation with advanced synovitis as shown in Figure 4e.
상기 실험예 1의 SF 데이터와는 대조적으로, 혈청 PlGF 수준은 TJC, SJC, CRP 또는 DAS28 점수와 상관관계를 보이지 않았으며(도 4b 참조), 혈청 PlGF 농도는 초음파 검사상 중증도에 따른 차이를 보이지 않았다. 항-혈관신생 단백질인 sFlt-1의 혈청 수준은 ESR 및 DAS28과 단지 보통 정도(modest)의 상관관계만을 보였으며, TJC, SJC, CRP 또는 GSUS와 PDUS 상 활막염 중증도와 어떠한 관련성을 보이지 않았다.In contrast to the SF data of Experimental Example 1, the serum PlGF level did not show a correlation with the TJC, SJC, CRP or DAS28 score (see FIG. 4B), and the serum PlGF concentration showed a difference according to the severity on ultrasound examination. Did. Serum levels of sFlt-1, an anti-angiogenic protein, showed only a moderate correlation with ESR and DAS28, and did not show any correlation with the severity of synovitis on TJC, SJC, CRP, or GSUS and PDUS.
종합하면, VEGF 및 IL-6의 혈청 수준은 혈청 PlGF와 혈청 sFlt1과 달리, 활막 증식 및 초음파 검사(US) 상 과맥관질(hyper-vascularity)을 나타내는 것이며, 이는 TJC, SJC, ESR, CRP 및 DAS28 점수로 평가한 RA의 전신 염증 상태를 반영하는 것임을 알 수 있었다.Taken together, the serum levels of VEGF and IL-6 are indicative of synovial proliferation and hyper-vascularity on ultrasound (US), unlike serum PlGF and serum sFlt1, which are TJC, SJC, ESR, CRP and It was found that it reflects the systemic inflammatory state of RA evaluated by the DAS28 score.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야 한다.The above description of the present invention is for illustrative purposes only, and those of ordinary skill in the art to which the present invention pertains will be able to understand that other specific forms can be easily modified without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not limiting.
<110> CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION <120> Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof <130> MP19-289 <160> 2 <170> KoPatentIn 3.0 <210> 1 <211> 149 <212> PRT <213> Homo sapiens <400> 1 Met Pro Val Met Arg Leu Phe Pro Cys Phe Leu Gln Leu Leu Ala Gly 1 5 10 15 Leu Ala Leu Pro Ala Val Pro Pro Gln Gln Trp Ala Leu Ser Ala Gly 20 25 30 Asn Gly Ser Ser Glu Val Glu Val Val Pro Phe Gln Glu Val Trp Gly 35 40 45 Arg Ser Tyr Cys Arg Ala Leu Glu Arg Leu Val Asp Val Val Ser Glu 50 55 60 Tyr Pro Ser Glu Val Glu His Met Phe Ser Pro Ser Cys Val Ser Leu 65 70 75 80 Leu Arg Cys Thr Gly Cys Cys Gly Asp Glu Asn Leu His Cys Val Pro 85 90 95 Val Glu Thr Ala Asn Val Thr Met Gln Leu Leu Lys Ile Arg Ser Gly 100 105 110 Asp Arg Pro Ser Tyr Val Glu Leu Thr Phe Ser Gln His Val Arg Cys 115 120 125 Glu Cys Arg Pro Leu Arg Glu Lys Met Lys Pro Glu Arg Cys Gly Asp 130 135 140 Ala Val Pro Arg Arg 145 <210> 2 <211> 191 <212> PRT <213> Homo sapiens <400> 2 Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5 10 15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly 20 25 30 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln 35 40 45 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu 50 55 60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu 65 70 75 80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro 85 90 95 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His 100 105 110 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys 115 120 125 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly 130 135 140 Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr 145 150 155 160 Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln 165 170 175 Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg 180 185 190 <110> CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION <120> Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof <130> MP19-289 <160> 2 <170> KoPatentIn 3.0 <210> 1 <211> 149 <212> PRT <213> Homo sapiens <400> 1 Met Pro Val Met Arg Leu Phe Pro Cys Phe Leu Gln Leu Leu Ala Gly 1 5 10 15 Leu Ala Leu Pro Ala Val Pro Pro Gln Gln Trp Ala Leu Ser Ala Gly 20 25 30 Asn Gly Ser Glu Val Glu Val Val Pro Phe Gln Glu Val Trp Gly 35 40 45 Arg Ser Tyr Cys Arg Ala Leu Glu Arg Leu Val Asp Val Val Ser Glu 50 55 60 Tyr Pro Ser Glu Val Glu His Met Phe Ser Pro Ser Cys Val Ser Leu 65 70 75 80 Leu Arg Cys Thr Gly Cys Cys Gly Asp Glu Asn Leu His Cys Val Pro 85 90 95 Val Glu Thr Ala Asn Val Thr Met Gln Leu Leu Lys Ile Arg Ser Gly 100 105 110 Asp Arg Pro Ser Tyr Val Glu Leu Thr Phe Ser Gln His Val Arg Cys 115 120 125 Glu Cys Arg Pro Leu Arg Glu Lys Met Lys Pro Glu Arg Cys Gly Asp 130 135 140 Ala Val Pro Arg Arg 145 <210> 2 <211> 191 <212> PRT <213> Homo sapiens <400> 2 Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5 10 15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly 20 25 30 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln 35 40 45 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu 50 55 60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu 65 70 75 80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro 85 90 95 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His 100 105 110 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys 115 120 125 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly 130 135 140 Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr 145 150 155 160 Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln 165 170 175 Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg 180 185 190
Claims (11)
At least one protein selected from the group consisting of placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF); Or a composition for diagnosing pannus of rheumatoid arthritis, comprising an agent for measuring the expression level of the mRNA encoding it.
상기 PlGF는 피검체로부터 채취된 활액(synovial fluid)에서 WBC counts, %호중구, ESR(erythrocyte sedimentation rate), CRP(C reactive protein), GSUS(Grey scale ultrasonography), 및 PDUS(power-Doppler ultrasonography)로 이루어진 군으로부터 선택되는 하나 이상과 양의 상관관계를 가지는 것을 특징으로 하는, 조성물.
The method of claim 1,
In the synovial fluid collected from the subject, the PlGF was measured by WBC counts,% neutrophils, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), gray scale ultrasonography (GSUS), and power-Doppler ultrasonography (PDUS). Composition, characterized in that it has a positive correlation with at least one selected from the group consisting of.
상기 VEGF는 피검체로부터 채취된 혈청(serum)에서 TJC(tender joint count), SJC(swollen joint count), ESR, CRP, DAS 28(disease activity score 28), GSUS, 및 PDUS로 이루어진 군으로부터 선택되는 하나 이상과 양의 상관관계를 가지는 것을 특징으로 하는, 조성물.
The method of claim 1,
The VEGF is selected from the group consisting of TJC (tender joint count), SJC (swollen joint count), ESR, CRP, DAS 28 (disease activity score 28), GSUS, and PDUS in serum collected from the subject. Composition, characterized in that it has a positive correlation with one or more.
상기 제제는 PlGF 및 VEGF로 이루어진 군으로부터 선택되는 하나 이상의 단백질; 또는 이를 코딩하는 mRNA에 특이적으로 결합하는 항체, 앱타머, 리간드, PNA(peptide nucleic acid), 올리고펩티드, 안티센스 올리고뉴클레오티드, 프라이머 쌍 및 프로브로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 조성물.
The method of claim 1,
The agent comprises at least one protein selected from the group consisting of PlGF and VEGF; Or the composition characterized in that it is at least one selected from the group consisting of antibodies, aptamers, ligands, peptide nucleic acids (PNA), oligopeptides, antisense oligonucleotides, primer pairs, and probes that specifically bind to the mRNA encoding the same. .
A kit for diagnosing pannus of rheumatoid arthritis, comprising the composition of claim 1.
(b) 채취된 시료에서의 PlGF(placenta growth factor) 단백질 또는 이를 코딩하는 mRNA의 발현 수준, 또는 VEGF(vascular endothelial growth factor) 단백질 또는 이를 코딩하는 mRNA의 발현 수준을 확인하는 단계를 포함하는, 류마티스 관절염의 판누스(pannus) 진단을 위한 정보제공방법.
(a) collecting a sample from the subject; And
(b) Rheumatoid, comprising the step of confirming the expression level of the PLGF (placenta growth factor) protein or the mRNA encoding the same in the collected sample, or the vascular endothelial growth factor (VEGF) protein or the expression level of the mRNA encoding the same. Information provision method for diagnosing pannus of arthritis.
상기 시료는 활액 또는 혈청인 것을 특징으로 하는, 정보제공방법.
The method of claim 6,
The method for providing information, characterized in that the sample is synovial fluid or serum.
(c) 상기 PlGF 단백질, 또는 이를 코딩하는 mRNA의 발현 수준이 활액 시료에서 정상 대조군에 비해 증가된 경우; 또는
상기 VEGF 단백질 또는 이를 코딩하는 mRNA의 발현 수준이 혈청 시료에서정상 대조군에 비해 증가된 경우 판누스 증식 정도가 높은 것으로 진단하는 단계를 더 포함하는 것을 특징으로 하는, 정보제공방법.
The method of claim 6,
(c) when the expression level of the PlGF protein, or mRNA encoding it, is increased in synovial fluid samples compared to the normal control; or
When the expression level of the VEGF protein or the mRNA encoding the same is increased compared to the normal control in the serum sample, the method further comprising diagnosing that the degree of pannus proliferation is high.
(b) 상기 후보물질 처리 후 PlGF 단백질 또는 이를 코딩하는 mRNA 발현 수준, 또는 VEGF 단백질 또는 이를 코딩하는 mRNA 발현 수준을 후보물질 처리 전과 비교하는 단계를 포함하는, 류마티스 관절염의 판누스 억제용 후보물질의 스크리닝 방법.
(a) treating a candidate material to cells expressing placenta growth factor (PlGF) or vascular endothelial growth factor (VEGF); And
(b) Comprising the step of comparing the expression level of PlGF protein or the mRNA encoding the same, or the expression level of the VEGF protein or the mRNA encoding the same after treatment with the candidate substance, and comparing the expression level of the VEGF protein or the mRNA encoding the same with before treatment of the candidate substance. Screening method.
(c) 상기 후보물질 처리 후 활액에서의 PlGF 단백질 또는 이를 코딩하는 mRNA 발현 수준이 후보물질 처리 전에 비해 감소한 경우; 또는
혈청에서의 VEGF 단백질 또는 이를 코딩하는 mRNA 발현 수준이 후보물질 처리 전에 비해 감소한 경우, 상기 후보물질을 류마티스 관절염의 판누스 억제용 후보물질로 선택하는 단계를 더 포함하는 것을 특징으로 하는, 스크리닝 방법.
The method of claim 9,
(c) When the expression level of PlGF protein or mRNA encoding it in synovial fluid after treatment with the candidate substance is decreased compared to before treatment with the candidate substance; or
When the expression level of the VEGF protein or the mRNA encoding the same in the serum decreases compared to before treatment with the candidate substance, the method further comprising the step of selecting the candidate substance as a candidate substance for pannus inhibition of rheumatoid arthritis.
상기 후보물질은 뉴클레오티드, DNA, RNA, 아미노산, 앱타머, 단백질, 화합물, 천연물, 및 천연추출물로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 스크리닝 방법.The method of claim 9,
The candidate material is characterized in that at least one selected from the group consisting of nucleotides, DNA, RNA, amino acids, aptamers, proteins, compounds, natural products, and natural extracts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190141956A KR102596937B1 (en) | 2019-11-07 | 2019-11-07 | Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190141956A KR102596937B1 (en) | 2019-11-07 | 2019-11-07 | Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210055856A true KR20210055856A (en) | 2021-05-18 |
| KR102596937B1 KR102596937B1 (en) | 2023-11-03 |
Family
ID=76158593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190141956A KR102596937B1 (en) | 2019-11-07 | 2019-11-07 | Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102596937B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230080657A (en) | 2021-11-30 | 2023-06-07 | 충남대학교산학협력단 | Method of Providing Information for Diagnosis or Remission-Assessment of Rheumatoid Arthritis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120104517A (en) * | 2009-09-03 | 2012-09-21 | 제넨테크, 인크. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| KR20190000212A (en) | 2017-06-22 | 2019-01-02 | 한국과학기술원 | SNP marker set for predicting of prognosis of rheumatoid arthritis |
-
2019
- 2019-11-07 KR KR1020190141956A patent/KR102596937B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120104517A (en) * | 2009-09-03 | 2012-09-21 | 제넨테크, 인크. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| KR20190000212A (en) | 2017-06-22 | 2019-01-02 | 한국과학기술원 | SNP marker set for predicting of prognosis of rheumatoid arthritis |
Non-Patent Citations (2)
| Title |
|---|
| Journal of Cellular Physiology, 2013, 228권, 페이지 983-990 * |
| The Journal of Immunology, 2003, 171권, 페이지 4853-4859 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230080657A (en) | 2021-11-30 | 2023-06-07 | 충남대학교산학협력단 | Method of Providing Information for Diagnosis or Remission-Assessment of Rheumatoid Arthritis |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102596937B1 (en) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rosu et al. | IL-17 patterns in synovium, serum and synovial fluid from treatment-naive, early rheumatoid arthritis patients | |
| US7846674B2 (en) | Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6 | |
| EP1721162B1 (en) | Method of assessing rheumatoid arthritis by measuring anti-ccp and serum amyloid a | |
| JP4610605B2 (en) | Method for evaluating rheumatoid arthritis by measuring rheumatoid factor and interleukin-6 | |
| zur Wiesch et al. | Pediatric rheumatology Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis | |
| KR20160046828A (en) | Methods and kits for predicting the risk of having a cardiovascular disease or event | |
| Nam et al. | The role of biomarkers in the management of patients with rheumatoid arthritis | |
| KR102596937B1 (en) | Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof | |
| KR20180014419A (en) | Biomarkers for diagnosing rheumatoid arthritis | |
| KR102481470B1 (en) | Biomarker for evaluating disease activity of rheumatoid arthritis and use thereof | |
| EP2791686B1 (en) | Tenascin-c and use thereof in rheumatoid arthritis | |
| JP2011107116A (en) | Inspection method of cerebral infarction | |
| KR101686877B1 (en) | A kit for Diagnosing or Prognostic Analysis of IgA nephropathy, including agent measuring the GDF15 expression level | |
| Sas | Neutrophil/lymphocyte and platelet/lymphocyte ratios are associated with disease activity in rheumatoid arthritis | |
| WO2019121187A1 (en) | Detection of autoantibodies for diagnosing degenerative diseases of the skeletal system | |
| EP3056904A1 (en) | Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-MCM3 | |
| EP3056903A1 (en) | Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-Casp8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) |